Chimeric Transcript Discovery by Paired-end Transcriptome Sequencing
Overview
Authors
Affiliations
Recurrent gene fusions are a prevalent class of mutations arising from the juxtaposition of 2 distinct regions, which can generate novel functional transcripts that could serve as valuable therapeutic targets in cancer. Therefore, we aim to establish a sensitive, high-throughput methodology to comprehensively catalog functional gene fusions in cancer by evaluating a paired-end transcriptome sequencing strategy. Not only did a paired-end approach provide a greater dynamic range in comparison with single read based approaches, but it clearly distinguished the high-level "driving" gene fusions, such as BCR-ABL1 and TMPRSS2-ERG, from potential lower level "passenger" gene fusions. Also, the comprehensiveness of a paired-end approach enabled the discovery of 12 previously undescribed gene fusions in 4 commonly used cell lines that eluded previous approaches. Using the paired-end transcriptome sequencing approach, we observed read-through mRNA chimeras, tissue-type restricted chimeras, converging transcripts, diverging transcripts, and overlapping mRNA transcripts. Last, we successfully used paired-end transcriptome sequencing to detect previously undescribed ETS gene fusions in prostate tumors. Together, this study establishes a highly specific and sensitive approach for accurately and comprehensively cataloguing chimeras within a sample using paired-end transcriptome sequencing.
Tan Y, Mohanty V, Liang S, Dou J, Ma J, Kim K J Bioinform Syst Biol. 2024; 6(2):74-81.
PMID: 39301431 PMC: 11412692. DOI: 10.26502/jbsb.5107050.
Biomarkers for Prostate Cancer: From Diagnosis to Treatment.
Chen J, Wang P, Liu M, Lyu F, Ma M, Ren X Diagnostics (Basel). 2023; 13(21).
PMID: 37958246 PMC: 10649216. DOI: 10.3390/diagnostics13213350.
Fast and sensitive validation of fusion transcripts in whole-genome sequencing data.
Hafstad V, Hakkinen J, Persson H BMC Bioinformatics. 2023; 24(1):359.
PMID: 37741966 PMC: 10518092. DOI: 10.1186/s12859-023-05489-5.
Disrupted in renal carcinoma 2 (DIRC2/SLC49A4) is an H-driven lysosomal pyridoxine exporter.
Akino S, Yasujima T, Yamashiro T, Yuasa H Life Sci Alliance. 2022; 6(2).
PMID: 36456177 PMC: 9719028. DOI: 10.26508/lsa.202201629.
The evolving landscape of prostate cancer somatic mutations.
Cotter K, Rubin M Prostate. 2022; 82 Suppl 1:S13-S24.
PMID: 35657155 PMC: 9328313. DOI: 10.1002/pros.24353.